Remarkable cost advantage of industrial production of retroviral vector: brilliant speech of founder

From June 27 to 28, 2022, the 4th Biomedicine Future Leaders Summit 2022 was held in Shenzhen, Guangdong, as scheduled. Professor Shi Yuanyuan, the founder of Shenzhen Cell Valley, was invited to participate in the meeting and published "Retrovirus or Lentivirus? That is the question." This is a wonderful keynote speech to discuss the industrial production of different virus vectors in cell therapy. 2022年6月27日—28日，Biofuture 2022第四届生物医药未来领袖峰会在广东深圳如期举行，深圳细胞谷创始人史渊源教授受邀参会，并发表题为《Retrovirus or Lentivirus? That is the question.》（逆病毒还是慢病毒载体？这是个问题。）的精彩主题演讲，探讨不同的病毒载体在细胞治疗中的工业化生产问题。

    The 21st century is the era of cell therapy. Due to the high threshold of retroviral vector technology, only a few enterprises in the world have mastered the industrial production technology of retroviral vector. Shenzhen Cell Valley is the only company in China that can produce clinical and industrial retroviral vectors. At the summit, Professor Shi Yuanyuan traced the development history of retroviral vector and lentiviral vector in view of the long-standing dispute over whether to use retroviral vector or lentiviral vector; The advantages of retrovirus vector compared with lentivirus vector in industrial production such as production cost, production mode, amount of packaging plasmid, quality control, and transduction efficiency were explained.21世纪是细胞治疗的时代，由于逆病毒载体技术门槛较高，全球只有少量企业掌握了逆病毒载体工业化生产技术，而深圳细胞谷是国内唯一可生产临床级及工业级逆转录病毒载体的公司。在此次峰会上，史渊源教授针对长久以来关于使用逆病毒载体还是慢病毒载体这个争议问题上，追溯了逆病毒载体与慢病毒载体的发展历史；讲解了逆病毒载体相对于慢病毒载体在生产成本、生产方式、包装质粒用量、质量控制、转导效率等工业化生产优势。

    随后，重点介绍了逆病毒载体在生产成本方面的巨大优势—逆病毒载体所需质粒用量为慢病毒载体所需质粒用量的千分之一，大大缩减了其生产成本。同时，史渊源教授从逆病毒及慢病毒载体在基因组中的插入方式及对内源基因表达的影响等角度，解释了逆病毒载体与慢病毒载体用于细胞治疗产品生产的安全性。根据最新的全球临床研究表明，在CAR-T等细胞治疗的安全性研究中，逆病毒和慢病毒两种载体表现出了同样好的安全性，打破了以往国内研发者们认为的逆病毒安全性存在问题的传统观念。Then, the great advantage of retroviral vector in production cost was introduced emphatically - the amount of plasmid required by retroviral vector was one thousandth of that required by lentiviral vector, which greatly reduced its production cost. At the same time, Professor Shi Yuanyuan explained the safety of retrovirus and lentivirus vectors used in the production of cell therapy products from the perspectives of the insertion mode of retrovirus and lentivirus vectors in the genome and their impact on endogenous gene expression. According to the latest global clinical research, in the research on the safety of cell therapy such as CAR-T, retrovirus and lentivirus have shown the same good safety, breaking the traditional idea that retrovirus safety is problematic, which was previously believed by domestic researchers.

    After Professor Shi Yuanyuan's wonderful sharing, many relevant scholars and experts in the field of cellular immunotherapy held a heated discussion and actively raised questions. Professor Shi Yuanyuan answered the relevant questions one by one. It also showed the domestic counterparts in the field of cell therapy that the current international R&D pipeline using retroviral vectors has exceeded the survey data of lentiviral vectors, which brought many new ideas and inspiration to the audience and won warm applause from the audience.史渊源教授的精彩分享结束后，众多细胞免疫治疗领域的相关学者、专家展开热烈讨论并积极提出问题，史渊源教授针对相关问题进行了一一解答。并向国内细胞治疗领域的同行们展示了当前国际上使用逆病毒载体的研发管线已经超过了慢病毒载体的调研数据，为在场观众们带来了很多新的理念和启发，赢得了在场观众热烈的掌声。